Award of Share Options

RNS Number : 5338X
hVIVO plc
13 August 2018
 

hVIVO PLC

("hVIVO" or the "Company")

 

Award of Share Options

 

London, UK, 13 August 2018: hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development and drug discovery services business, announces that on 10 August 2018 it awarded the following options over ordinary shares of 5.0p each in the Company to Graham Yeatman:

 

Name

Position

Number of Share Options Awarded

Exercise price per Share

Date of Vesting

Percentage of issued ordinary share capital

Graham Yeatman

Chief Financial & Business Officer

100,000

5.0p

10 August 2021

0.1%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the persons discharging managerial responsibilities/persons closely associated

a)

Name

Graham Yeatman

2

Reason for the notification

a)

Position/ status

Chief Financial & Business Officer

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

hVIVO plc

b)

Legal Entity Identifier

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Options over Ordinary Shares of 5 pence each

 

 

ISIN: GB00B6ZM0X53

b)

Nature of the transaction

Award of options over ordinary shares in the Company

c)

Currency

GBP

d)

Price(s) and volume(s)

Director

Exercise Price (p)

Volume

Graham Yeatman

5.0

100,000

 

e)

Aggregated information

- Aggregated volume

- Exercise price

 

 

Options over 100,000 ordinary shares

5.0p

f)

Date of the transaction

10 August 2018

g)

Place of the transaction

London Stock Exchange, AIM

 

 

For further information please contact:

 

hVIVO plc


Trevor Phillips (Executive Chairman)

+44 207 756 1300

Fleur Wood (Director, Investor Relations)

 

 

Numis Securities Limited

 +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)


James Black / Michael Burke (Corporate Broking)




FTI Consulting


Simon Conway / Victoria Foster Mitchell

+44 203 727 1000

 

 

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHURSBRWWAWAAR

Companies

Hvivo (HVO)
UK 100

Latest directors dealings